The True Cost of Australia's 43.5% R&D Tax Incentive for Clinical Trials
The rebate is real and genuinely valuable — for eligible companies. The question is whether you are one of them, and what the headline number costs you in time.
September 3, 2026
7
min read
By
Julio G. Martinez-Clark, CEO, bioaccess®
Australia
Latin America
First-in-Human
Clinical Trial Costs
R&D Tax Incentive
Medical Devices
Is the 43.5% rebate real?
Yes. Australia's R&D Tax Incentive is a real government program, not a marketing device, and for an eligible early-stage company it is one of the most useful non-dilutive funding mechanisms in the developed world. A 43.5% refundable tax offset on eligible R&D expenditure is serious capital for a company burning runway toward a first-in-human milestone. Sponsors who use it well are making a sound financial decision, and nothing below is a criticism of the program or of the Australian institutions that administer it.
The problem is not the incentive. The problem is how the incentive gets quoted in clinical trial proposals — as a flat 43.5% discount, applied immediately, available to everyone. Three qualifiers turn that headline into something materially smaller for most US device sponsors: who qualifies, what it takes to claim, and when the money actually lands.
Read the program terms at the source. The ATO and AusIndustry R&D Tax Incentive program pages define eligibility and the refundable-versus-non-refundable split; Silicon Valley Bank's "The Advantage of Oz," datapharmaustralia.com, and ingenucro.com all discuss the program in a clinical trial context.
Who actually qualifies for the refundable offset?
The 43.5% figure is a refundable offset available only to companies with aggregated turnover under A$20M. Companies at or above A$20M aggregated turnover receive a 38.5% non-refundable offset instead — and the word non-refundable does the heavy lifting there. A non-refundable offset reduces Australian tax payable. If you have no Australian tax liability, it does not become cash.
So the first honest question is not "how big is the rebate," it is "which rebate am I even eligible for." Aggregated turnover is a group-level concept, not just the local entity's revenue, which means a well-funded company with commercial revenue elsewhere can find itself on the wrong side of the ceiling precisely when it is running its most expensive study.
What does it take to claim it?
The incentive is not something a US company can invoice for. Claiming it requires real structure on the ground:
- An Australian incorporated entity or a permanent establishment — you must have a claimant that exists under Australian law.
- Registration with AusIndustry for the R&D activities you intend to claim.
- At least A$20,000 of eligible R&D expenditure.
- Local legal and accounting support to register the activities, substantiate the spend, and lodge the claim.
None of that is unreasonable — a government funding a domestic R&D base should require a domestic claimant. But each item is time, professional fees, and administrative surface area that lands on a small clinical and regulatory team that would otherwise be running the study. It is a real cost, and it is almost never subtracted from the headline 43.5% in a proposal.
When does the cash actually arrive?
This is the qualifier that changes decisions. The refund is not immediate. It arrives after the Australian tax-year lodgment — typically 12-18 months after the money was spent. In the meantime, your bank account carries 100% of the study cost.
For a venture-backed device company, 12-18 months is not an accounting detail. It is a financing event. It is the difference between reaching a first-in-human data milestone before your next raise and reaching it after. A rebate that lands a fiscal cycle late functions as a loan you make to your own program at the exact moment your runway is tightest.
What does a US$1.00 of spend really return?
Take the simplest possible case. You spend US$1.00 on eligible R&D in Australia today. You get about US$0.435 back next fiscal year — and only if you are under the A$20M ceiling and already have the entity in place. Before that, you carry the full US$1.00 for 12-18 months.
| Question | Australia (R&D Tax Incentive) | Latin America with bioaccess® |
|---|---|---|
| What do you pay today? | The full US$1.00. | Roughly the post-rebate net, pay-as-you-go. |
| What comes back, and when? | About US$0.435, typically 12-18 months after the spend, following tax-year lodgment. | Nothing comes back later because nothing was overpaid up front. |
| Who is eligible? | Refundable 43.5% only under A$20M aggregated turnover; 38.5% non-refundable at or above it. | No turnover test applies. |
| What structure is required? | Australian incorporated entity or permanent establishment, AusIndustry registration, at least A$20,000 eligible spend, local legal and accounting. | No Australian entity to stand up; bioaccess® provides in-country regulatory infrastructure. |
| What is the cash-flow effect? | Full cost carried for 12-18 months before any refund. | No 12-18 month cash lag. |
How does pay-as-you-go Latin America compare?
Running the same first-in-human work in Latin America with bioaccess® is pay-as-you-go at roughly the post-rebate net cost. You are not buying a discount on the back end; you are simply not spending the money on the front end. There is no Australian entity to incorporate, no turnover ceiling to monitor, no AusIndustry registration to maintain, and no 12-18 month gap between spend and recovery.
Cost is only one of the four variables that decide an early device study, and this post deliberately covers only that one. The full comparison — approval speed, recruitment catchment, skin-type diversity, travel, and entity requirements — is in the pillar: Australia vs. Latin America for first-in-human medical device trials. Enrollment feasibility is covered in the catchment math behind Australian recruitment, and activation timing in TGA CTN versus Latin America on first-patient-in timelines.
What is the honest takeaway?
The incentive rewards companies that are already Australian-resident and under the turnover cap. If that describes you, use it — it is a well-designed program and the arithmetic works in your favor. For a US sponsor without an Australian entity, the headline 43.5% overstates the real, risk-adjusted, time-value-adjusted benefit once you net out eligibility risk, the non-refundable fallback above A$20M, entity and professional costs, and 12-18 months of carried cost.
Model both scenarios on your own numbers before you commit a first-in-human budget. If you want the broader set of options, see alternatives to Australia for first-in-human trials in 2026, how we run studies in our first-in-human CRO practice, and what the same in-country infrastructure does for you afterward in Latin American market access.
Frequently asked questions
What is the fastest next step?
Send us your device, your cohort size, and your target first-patient-in date, and we will model the cash-flow difference against your actual budget — including the cases where the Australian incentive genuinely wins. Get a first-in-human feasibility read in 72 hours.
Get your feasibility read
See how we run first-in-human